BUCHANG PHARMA(SH:603858) Sou Hu Wang·2026-01-06 09:31Core Viewpoint - Recently, Buchang Pharma has gained market attention for its innovation in drug development, capital market returns, and commitment to public welfare, showcasing the company's responsibility and dedication in the pharmaceutical industry [1] Innovation Drug Pipeline - Buchang Pharma has made significant advancements in its innovation drug pipeline, covering three major areas: biopharmaceuticals, traditional Chinese medicine, and chemical drugs [2] - The company is accelerating the application of its first Class 1 new drug, Epoetin Alfa, targeting renal anemia and chemotherapy-induced anemia, which could fill a gap in the domestic long-acting EPO market valued at 15 billion [2] - The first biosimilar drug, Adalimumab injection, is under review, targeting multiple autoimmune diseases with substantial market potential [2] - The company is advancing its Class 1 biopharmaceutical BC001 for late-stage gastric cancer and has several targeted cancer drugs in critical clinical development stages [2][4] Traditional Chinese Medicine and Chemical Drug Expansion - In traditional Chinese medicine, the company has completed Phase II clinical trials for its Qi-tonifying granules and is set to start Phase II/III trials for its heart failure treatment granules in May 2025 [4] - In the chemical drug sector, Buchang Pharma has launched 17 new generic drugs in 2023, including products that target a 20 billion market for antiviral drugs and expand its muscle relaxant market [4] - The company has successfully renewed contracts for exclusive products in the 2025 National Medical Insurance Directory, with total sales exceeding 10.3 billion in the first three quarters [4] Shareholder Returns - Buchang Pharma has established a stable return mechanism for investors, with cumulative dividends reaching 7.948 billion and share buybacks totaling 1.744 billion since its listing [5] - In 2025, the company has repurchased 6.6206 million shares, with a total repurchase amount nearing 100 million, demonstrating confidence in its future development [5] Corporate Social Responsibility - Since its inception, Buchang Pharma has adhered to its mission of "creating health for humanity," actively engaging in social responsibility through the "Together, Build China's Heart" initiative for 18 years [6] - The initiative has expanded from congenital heart disease to various medical fields, providing comprehensive medical assistance to over 1 million patients [6] - The company has contributed nearly 33 billion in taxes nationwide, supporting regional economic development [6] Future Outlook - The chairman of Buchang Pharma, Zhao Tao, emphasized the company's commitment to innovation-driven development and social responsibility, aiming to lead industry growth and create greater social value [7]